Skip to main content
SpringerLink
Log in
Book cover

Replicating Vaccines pp 99–117Cite as

Live-Attenuated Shigella Vaccines. Is Encouraging Good Enough?

  • Chapter
  • First Online:

  • 921 Accesses

Part of the book series: Birkhäuser Advances in Infectious Diseases ((BAID))

Abstract

Several strategies have been used to develop vaccines against Shigella infection. Among these, the most tested has been the construction of live attenuated, orally administered vaccine candidates in which defined mutations were introduced in specific genes. Two major options exist: (1) altering key metabolic pathways affecting bacterial growth in tissues or (2) knocking out virulence genes selected upon their expected capacity to affect one or several key steps of the infectious process. In certain cases, the two options have been combined. Live-attenuated Shigella vaccine candidates have shown great promise. They elicited, in general, significant immune responses when administered orally to volunteers. They have the capacity to confer protection by eliciting both mucosal and systemic immune responses, particularly the intestinal production of secretory IgAs directed against the O-antigens, a series of complex surface sugars accounting for the bacterial serotypes, which are known to mediate protection following natural infection. These responses have been measured by evaluating antibody-secreting cells, serum antibody levels, and fecal IgA to O-antigens and individual virulence-related protein antigens for a dozen of vaccine candidates. Live-attenuated vaccines also offer the potential to elicit strong IFN-γ responses, a cytokine that is known to provide protection against Shigella infection. With regard to possible T-cell–mediated responses, much basic research is still warranted to optimize vaccine approaches. Owing to the wide range of Shigella serotypes and subtypes, there is a priori a need for a multivalent vaccine representing the prevalent species and serotypes. The barrier to the use of live vaccine candidates against shigellosis is the issue of multivalency and indications for an average to poor immune responses observed in infants and children in endemic areas. In addition, identification of the correlates of protection is needed to accelerate the development of these vaccines.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Von Seidlen L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, Canh do G, Chaicumpa W, Agtini MD, Hossain A et al (2006) A multicentre study of Shigella diarrhea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med 3:e353

    Article  Google Scholar 

  2. Cohen D, Green MS, Block C, Slepon R, Lerman Y (1992) Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide. J Infect Dis 165:785–787

    CAS  PubMed  Google Scholar 

  3. Sansonetti PJ (2004) War and peace at mucosal surface. Nat Rev Immunol 4:953–964

    Article  CAS  PubMed  Google Scholar 

  4. Heyman SN, Ginosar Y, Shapiro M, Kluger Y, Marx N, Maayan S (1997) Diarrheal epidemics among Rwandan refugees in 1994. Management and outcome in a field hospital. J Clin Gastroenterol 25(4):595–601

    Article  CAS  PubMed  Google Scholar 

  5. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine MM (1999) Global burden of Shigella infections: implication for vaccine development and implementation of control strategies. Bull World Health Organ 77:651–666

    CAS  PubMed  Google Scholar 

  6. Kosek M, Bern C, Guerrant RL (2003) The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 81:197–204

    PubMed  Google Scholar 

  7. Pazhani GP, Sarkar B, Ramamurthy T, Bhattacharya SK, Takeda Y, Niyogi SK (2004) Clonal multidrug-resistant Shigella dysenteriae type 1 strains associated with epidemic and sporadic dysenteries in eastern India. Antimicrob Agents Chemother 48(2):681–684

    Article  CAS  PubMed  Google Scholar 

  8. Nato F, Phalipon A, Nguyen TL, Diep TT, Sansonetti PJ, Germani Y (2007) Dipstick for rapid diagnosis of Shigella flexneri 2a in stool. PLoS ONE 2:e361

    Article  PubMed  CAS  Google Scholar 

  9. Venkatesan MM, Ranallo RT (2006) Live-attenuated Shigella vaccines. Expert Rev Vaccines 5:669–686

    Article  CAS  PubMed  Google Scholar 

  10. Gangarosa ML, Caceres E, Perera A, Mejicanos D (1970) Epidemic Shiga bacilllus dysentery in Central America (1969). I. Etiologic investigations in Guatemala. J Infect Dis 122:170–180

    PubMed  Google Scholar 

  11. Rahaman MM, Khan MM, Aziz KMS, Islam MS, Kibriya AK (1975) An outbreak of dysentery caused by Shigella dysenteriae type 1 on a coral island in the Bay of Bengal. J Infect Dis 132:15–19

    CAS  PubMed  Google Scholar 

  12. Moore EJR, EC SWR, Schaberg D, Kyle J, Ishida K (1984) Epidemic Shiga bacillus dysentery in Central Africa. Am J Trop Med Hyg 33:1192–1197

    PubMed  Google Scholar 

  13. Aragon M, Barreto A, Chambule J, Noya A, Tallarico M (1995) Shigellosis in Mozambique: the 1993 outbreak rehabilitation – a follow-up study. Trop Doct 25:159–162

    CAS  PubMed  Google Scholar 

  14. Birmingham ME, Lee LA, Ntakibirora M, Bizimana F, Deming MSA (1997) Household survey of dysentery in Burundi: implications for the current pandemic in sub-Saharan Africa. Bull World Health Organ 75:45–53

    CAS  PubMed  Google Scholar 

  15. Taylor D, Echeverria P, Pal T, Sethabutr O, Saiborisuth S, Sricharmorn S, Rowe B, Cross J (1986) The role of Shigella spp., enteroinvasive Escherichia coli and other enteropathogens as cause of childhood dysentery in Thailand. J Infect Dis 153:1132–1138

    CAS  PubMed  Google Scholar 

  16. Shane AL, Tucker NA, Crump JA, Mintz ED, Painter JA (2003) Sharing Shigella: risk factors for a multicommunity outbreak of shigellosis. Arch Pediatr Adolesc Med 157:601–603

    Article  PubMed  Google Scholar 

  17. Mohle-Boetani JC, Stapleton M, Finger R, Bean NH, Poundstone J, Blake PA, Griffin PM (1995) Communitywide shigellosis: control of an outbreak and risk factors in child day-care centers. Am J Public Health 85:812–816

    Article  CAS  PubMed  Google Scholar 

  18. Ferreccio C, Prado V, Ojeda A, Cayyazo M, Abrego P, Guers L, Levine MM (1991) Epidemiologic patterns of acute diarrhea and endemic Shigella infections in a poor periurban setting in Santiago, Chile. Am J Epidemiol 134:614–627

    CAS  PubMed  Google Scholar 

  19. Niyogi SK (2005) Shigellosis. J Microbiol 43:133–143

    PubMed  Google Scholar 

  20. Hyams KC, Bourgeois AL, Merrell BR, Rozmajzl P, Escamilla J, Thornton SA, Wasserman GM, Burke A, Echeverria P, Green KY et al (1991) Diarrheal disease during operation desert shield. N Engl J Med 325:1423–1428

    Article  CAS  PubMed  Google Scholar 

  21. Levine MM (2000) Immunization against bacterial diseases of the intestine. J Pediatr Gastroenterol Nutr 31:336–355

    Article  CAS  PubMed  Google Scholar 

  22. Phalipon A, Mulard LA, Sansonetti PJ (2008) Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path? Microbes Infect 10:1057–1062

    Article  CAS  PubMed  Google Scholar 

  23. Sansonetti PJ (2006) The innate signaling of dangers and the dangers of innate signaling. Nat Immunol 7:1237–1242

    Article  CAS  PubMed  Google Scholar 

  24. Germani Y, Sansonetti PJ (2003) The genus Shigella. In: Dworkin M et al (eds) The Prokaryotes, – A handbook on the biology of bacteria: ecophysiology, isolation, identification, applications, 3rd edn. Springer, New York) (http://rizzo.springer-ny.com:6336/contents/)

    Google Scholar 

  25. Bernardini ML, Mounier J, d'Hauteville H, Coquis-Rondon M, Sansonetti PJ (1989) Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin. Proc Natl Acad Sci USA 86:3867–3871

    Article  CAS  PubMed  Google Scholar 

  26. Sansonetti PJ, Arondel J, Fontaine A, d'Hauteville H, Bernardini ML (1991) OmpB (osmo-regulation) and icsA (cell-to-cell spread) mutants of Shigella flexneri: vaccine candidates and probes to study the pathogenesis of shigellosis. Vaccine 9:416–422

    Article  CAS  PubMed  Google Scholar 

  27. Nassif X, Mazert MC, Mounier J, Sansonetti PJ (1987) Evaluation with an iuc:Tn10 mutant of the role of aerobactin production in the virulence of Shigella flexneri. Infect Immun 55:1963–1969

    CAS  PubMed  Google Scholar 

  28. Fasano A, Noriega FR, Maneval DR Jr, Chanasongcram S, Russell R, Guandalini S, Levine MM et al (1995) Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest 95:2853–2861

    Article  CAS  PubMed  Google Scholar 

  29. Noriega FR, Liao FM, Formal SB, Fasano A, Levine MM (1995) Prevalence of Shigella enterotoxin 1 among Shigella clinical isolates of diverse serotypes. J Infect Dis 172:1408–1410

    CAS  PubMed  Google Scholar 

  30. Niyogi SK, Vargas M, Vila J (2004) Prevalence of the sat, set and sen genes among diverse serotypes of Shigella flexneri strains isolated from patients with acute diarrhoea. Clin Microbiol Infect 10:574–576

    Article  CAS  PubMed  Google Scholar 

  31. Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, Nataro JP, Picking WD, Barry EM, Levine MM et al (2000) Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun 68:1034–1039

    Article  CAS  PubMed  Google Scholar 

  32. Robbins JB, Chu CY, Schneerson R (1992) Hypothesis for vaccine development: protective immunity to enteric diseases caused by non-typhoidal Salmonella and Shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis 15:346–361

    CAS  PubMed  Google Scholar 

  33. Herrington DA, Van DeVerg L, Formal SB, Hale TL, Tall BD, Cryz SJ, Tramont EC, Levine MM (1990) Studies in volunteers to evaluate candidate Shigella vaccine: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8:353–357

    Article  CAS  PubMed  Google Scholar 

  34. Kotloff KL, Nataro JP, Losonsky GA, Wasserman SS, Hale TL, Taylor DN, Sadoff JC, Levine MM (1995) A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 13:1488–1494

    Article  CAS  PubMed  Google Scholar 

  35. Formal SB, Oaks EV, Olsen RE, Wingfield-Eggleston M, Snoy PJ, Cogan JP (1991) Effect of prior infection with Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J Infect Dis 164:534–537

    Google Scholar 

  36. Lindberg AA, Karnell A, Weintraub A (1991) The lipopolysaccharide of Shigella bacteria as a virulence factor. Rev Infect Dis 13:S279–S284

    CAS  PubMed  Google Scholar 

  37. Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB (2007) Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 5:540–553

    Article  CAS  PubMed  Google Scholar 

  38. Mel DM, Terzin AL, Vuksic L (1965) Studies on vaccination against bacillary dysentery. 1. Immunization of mice against experimental Shigella infection. Bull World Health Organ 32:633–636

    CAS  PubMed  Google Scholar 

  39. Mel DM, Gangarosa EJ, Radovanovic ML, Arsic BL, Litvinjenko S (1971) Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with Streptomycin-dependant Shigella strains. Bull World Health Organ 45:457–464

    CAS  PubMed  Google Scholar 

  40. Mel DM, Arsic BL, Nikolic BD, Radovanovic ML (1968) Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines. Bull World Health Organ 39:375–380

    CAS  PubMed  Google Scholar 

  41. Mel DM, Arsic BL, Radovanovic ML, Litvinjenko S (1974) Live oral Shigella vaccine: vaccination schedule and the effect of booster dose. Acta Microbiol Acad Sci Hung 21:109–114

    CAS  PubMed  Google Scholar 

  42. Mel DM, Papo RG, Terzin AL, Vuksic L (1965) Studies on vaccination against bacillary dysentery. 2. Safety tests and reactogenicity studies on a live dysentery vaccine intended for use in field trials. Bull World Health Organ 32:637–645

    CAS  PubMed  Google Scholar 

  43. DuPont HL, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Gangarosa EJ et al (1972) Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis 125:12–16

    CAS  PubMed  Google Scholar 

  44. Levine MM, Gangarosa EJ, Werner M, Morris JG (1974) Shigellosis in custodial institutions. III. Prospective clinical and bacteriologic surveillance of children vaccinated with oral attenuated Shigella vaccine. J Pediatr 84:803–806

    Article  CAS  PubMed  Google Scholar 

  45. DuPont HL, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Gangarosa EJ et al (1972) Immunity in shigellosis. I. Response of man to attenuated strains of Shigella. J Infect Dis 125:5–11

    CAS  PubMed  Google Scholar 

  46. Levine MM, Dupont HL, Gangarosa EJ, Hornick RB, Snyder MJ, Libonati JP, Glaser K, Formal SB (1972) Shigellosis in custodial institutions. II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated Shigella vaccines. Am J Epidemiol 96:40–49

    CAS  PubMed  Google Scholar 

  47. Dupont LMM, HL GEJ, Hornick RB, Snyder MJ, Libonati JP, Glaser K, Formal SB (1975) Shigellosis in custodial institutions. IV. In vivo stability and transmissibility of oral attenuated streptomycin-dependent Shigella vaccines. J Infect Dis 131:704–707

    Google Scholar 

  48. Levine MM, Gangarosa EJ, Barrow WB, Weiss CF (1976) Shigellosis in custodial institutions. V. Effect of intervention with streptomycin-dependent Shigella sonnei vaccine in an institution with endemic disease. Am J Epidemiol 104:88–92

    CAS  PubMed  Google Scholar 

  49. Damjanovic V (1972) Freeze-drying of live oral streptomycin dependent mutant Shigella vaccines: survival of streptomycin-dependent Shigella flexneri 2a after freeze-drying. Cryobiology 9:565–568

    Article  CAS  PubMed  Google Scholar 

  50. Phalipon A, Sansonetti PJ (2007) Shigella’s ways of manipulating the host intestinal innate and adaptative immune system: a tool box for survival? Immunol Cell Biol 85:119–129

    Article  CAS  PubMed  Google Scholar 

  51. Formal SB, LaBrec EH, Palmer A, Falkow S (1965) Protection of monkeys against experimental shigellosis with attenuated vaccines. J Bacteriol 90:63–68

    CAS  PubMed  Google Scholar 

  52. Falkow S, Schneider H, Baron LS, Formal SB (1963) Virulence of Escherichia–Shigella genetic hybrids for the guinea pig. J Bacteriol 86:1251–1258

    CAS  PubMed  Google Scholar 

  53. Istrati G, Istrati M, Meitert T, Ciufeco C (1965) Genetic stability of the nonpathogenic and antiinfectious immunogenic character of some strains of Sh. flexneri 2a. Arch Roum Pathol Exp Microbiol 24:867–874

    CAS  PubMed  Google Scholar 

  54. Bingrui W (1984) Study on the effect of oral immunization of T32-Istrati strain against bacillary dysentery in field trials. Arch Roum Pathol Exp Microbiol 43:285–289

    CAS  PubMed  Google Scholar 

  55. Meitert T, Istrati G, Sulea IT, Baron E, Andronescu C, Gogulescu L, Templea C, Ianopol L, Galan L, Fleşeriu M et al (1973) Prophylaxie de la dysenterie bacillaire par le vaccin vivant antidysentérique dans une collectivité d’enfants neuropsychiques. Arch Roum Pathol Exp Microbiol 32:35–44

    CAS  PubMed  Google Scholar 

  56. Meitert T, Pencu E, Ciudin L, Tonciu M (1984) Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati). Arch Roum Pathol Exp Microbiol 43:251–278

    CAS  PubMed  Google Scholar 

  57. World Health Organization http://www.who.int/vaccine_research/diseases/diarrhoeal/en/

  58. Kweon M-N (2008) Shigellosis: the current status of vaccine development. Curr Opin Infect Dis 21:313–318

    Article  CAS  PubMed  Google Scholar 

  59. Tu G (1999) Double-blind field trial of oral live F2a– Sonnei (FS) dysentery vaccine. J Biol Prod 12:178–180

    Google Scholar 

  60. Karnell A, Li A, Zhao CR, Karlsson K, Nguyen BM, Lindberg AA (1995) Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers. Vaccine 13:88–89

    Article  CAS  PubMed  Google Scholar 

  61. Kotloff KL, Noriega F, Losonsky GA, Sztein MB, Wasserman SS, Nataro JP, Levine MM et al (1996) Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun 64:4542–4548

    CAS  PubMed  Google Scholar 

  62. Li A, Cam PD, Islam D, Minh NB, Huan PT, Rong ZC, Karlsson K, Lindberg G, Lindberg AA (1994) Immune responses in Vietnamese children after a single dose of the auxotrophic, live Shigella Y vaccine strain SFL124. J Infect 28:11–23

    Article  CAS  PubMed  Google Scholar 

  63. Huan PT, Taylor R, Lindberg AA, Verma NK (1995) Immunogenicity of the Shigella flexneri serotype Y (SFL 124) vaccine strain expressing cloned glucosyl transferase gene of converting bacteriophage SfX. Microbiol Immunol 39:467–472

    CAS  PubMed  Google Scholar 

  64. Huan PT, Bastin DA, Whittle BL, Lindberg AA, Verma NK (1997) Molecular characterization of the genes involved in O-antigen modification, attachment, integration and excision in Shigella flexneri bacteriophage SfV. Gene 195:217–227

    Article  CAS  PubMed  Google Scholar 

  65. Adhikari P, Allison G, Whittle B, Verma NK (1999) Serotype 1a O-antigen modification: molecular characterization of the genes involved and their novel organization in the Shigella flexneri chromosome. J Bacteriol 181:4711–4718

    CAS  PubMed  Google Scholar 

  66. Guan S, Bastin DA, Verma NK (1999) Functional analysis of the O antigen glucosylation gene cluster of Shigella flexneri bacteriophage SfX. Microbiology 145:1263–1273

    Article  CAS  PubMed  Google Scholar 

  67. Adams MM, Allison GE, Verma NK (2001) Type IV O antigen modification genes in the genome of Shigella flexneri NCTC 8296. Microbiology 147:851–860

    CAS  PubMed  Google Scholar 

  68. Allison GE, Angeles D, Tran-Dinh N, Verma NK (2002) Complete genomic sequence of SfV, a serotype-converting temperate bacteriophage of Shigella flexneri. J Bacteriol 184:1974–1987

    Article  CAS  PubMed  Google Scholar 

  69. Noriega FR, Wang JY, Losonsky G, Maneval DR, Hone FM, Levine MM (1994) Engineered DguaBA, DvirG Shigella flexneri 2a strain CVD1205: construction, safety, immunogenicity and protective efficacy as a mucosal vaccine. Infect Immun 64:3055–3061

    Google Scholar 

  70. Sansonetti PJ, Arondel J (1991) Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine 7:443–450

    Article  Google Scholar 

  71. Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL (1999) Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 67:3437–3443

    CAS  PubMed  Google Scholar 

  72. Seid RC, Kopecko DJ, Sadoff JC, Schneider H, Baron LS, Formal SB (1984) Unusual lipopolysaccharide antigens of a Salmonella typhi oral vaccine strain expressing the Shigella sonnei form I antigen. J Biol Chem 259:9028–9034

    CAS  PubMed  Google Scholar 

  73. Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, Levine MM, Hale TL (2002) Phase I evaluation of a virG deleted Shigella sonnei live, attenuated vaccine (Strain WRSS1) in healthy adult volunteers. Infect Immun 70:2016–2021

    Article  CAS  PubMed  Google Scholar 

  74. Ranallo RT, Thakkar S, Chen Q, Venkatesan MM (2007) Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. Vaccine 25:2269–2278

    Article  CAS  PubMed  Google Scholar 

  75. Black RE, Levine MM, Clements ML, Losonsky G, Herrington D, Berman S, Formal SB (1987) Prevention of shigellosis by a Salmonella typhi–Shigella sonnei bivalent vaccine. J Infect Dis 155:1260–1265

    CAS  PubMed  Google Scholar 

  76. Orr N, Katz DE, Atsmon J, Radu P, Yavzori M, Halperin T, Sela T, Kayouf R, Klein Z, Ambar R, Cohen D et al (2005) Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun 73:8027–8032

    Article  CAS  PubMed  Google Scholar 

  77. Collins TA, Barnoy S, Baqar S, Ranallo RT, Nemelka KW, Venkatesan MM (2008) Safety and colonization of two novel VirG(IcsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta). Comp Med 58:88–94

    CAS  PubMed  Google Scholar 

  78. Lewis D (2004) Update on the clinical trials of SC599 at WHO meeting on future needs and directions of Shigella vaccines, 13–15 September 2004, Geneva, Switzerland

    Google Scholar 

  79. Sadorge C, Ndiaye A, Beveridge N, Frazer S, Giemza R, Jolly N, Johnson J, Liddy H, Cosgrove CA, Allavena P, Mantovani A et al (2008) Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 _icsA _ent _fep _stxA:HgR oral vaccine SC599 in healthy human adult volunteers. Vaccine 26:978–987

    Article  CAS  PubMed  Google Scholar 

  80. Launay O, Sadorge C, Jolly N, Poirier B, Béchet S, van der Vliet D, Seffer V, Fenner N, Dowling K, Giemza R et al (2009) Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial. Vaccine 27:1184–1191

    Article  CAS  PubMed  Google Scholar 

  81. Venkatesan MM, Hartman AB, Newland JW et al (2002) Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine. Infect Immun 70:2950–2958

    Article  CAS  PubMed  Google Scholar 

  82. Noriega FR, Liao FM, Maneval DR, Ren S, Formal SB, Levine MM (1999) Strategy for cross protection among Shigella flexneri serotypes. Infect Immun 67:782–788

    CAS  PubMed  Google Scholar 

  83. Noriega FR, Wang JY, Losonsky G et al (1994) Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect Immun 62:5168–5172

    CAS  PubMed  Google Scholar 

  84. Nataro JP, Seriwatana J, Fasano A, Maneval DR, Guers LD, Noriega F, Dubovsky F, Levine MM, Morris JG Jr (1995) Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun 63:4721–4728

    CAS  PubMed  Google Scholar 

  85. Kotloff KL, Pasetti MF, Barry EM et al (2004) Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J Infect Dis 190:1745–1754

    Article  CAS  PubMed  Google Scholar 

  86. Kotloff KL, Simon JK, Pasetti MF, Sztein MB, Wooden SL, Livio S, Nataro JP, Blackwelder WC, Barry EM, Picking W, Levine MM (2007) Safety and immunogenicity of CVD 12058, a live, oral D gna BA D sen D set Shigella flexneri 2a vaccine grown on animal free media. Hum Vaccin 3:268–275

    CAS  PubMed  Google Scholar 

  87. Simon JK, Wahid R, Maciel M Jr, Picking WL, Kotloff KL, Levine MM, Sztein MB (2009) Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates. Vaccine 27:565–572

    Article  CAS  PubMed  Google Scholar 

  88. Levine MM, Woodward WE, Formal SB, Gemski P Jr, DuPont HL, Hornick RB, Snyder MJ (1977) Studies with a new generation of oral attenuated Shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri. J Infect Dis 136:577–582

    CAS  PubMed  Google Scholar 

  89. Kotloff KL et al (1992) Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect Immun 60:2218–2224

    CAS  PubMed  Google Scholar 

  90. Newland JW, Hale TL, Formal SB (1992) Genotypic and phenotypic characterization of an aroD deletion attenuated Escherichia coli K12–Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen. Vaccine 10:766–776

    Article  CAS  PubMed  Google Scholar 

  91. Formal SB, Baron LS, Kopecko DJ, Washington O, Powell C, Life CA (1981) Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain. Infect Immun 34:746–750

    CAS  PubMed  Google Scholar 

  92. Tramont EC, Chung R, Berman S, Keren D, Kapfer C, Formal SB (1984) Safety and antigenicity of typhoid-Shigella sonnei vaccine (strain 5076–1C). J Infect Dis 149:133–136

    CAS  PubMed  Google Scholar 

  93. Van de Verg L et al (1990) Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi–Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect Immun 58:2002–2004

    PubMed  Google Scholar 

  94. Lagos R, Fasano A, Wasserman SS et al (1999) Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis 180:1709–1712

    Article  CAS  PubMed  Google Scholar 

  95. Walker RI, Van De Verg LL, Hall R, Schmitt CK, Woo K, Hale V (2005) Enteric vaccines for pediatric use. Workshop summary. Vaccine 23:5432–5439

    Article  CAS  PubMed  Google Scholar 

  96. Cooper PJ, Chico ME, Losonsky G (2000) Albendazole® treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated cholera vaccine CVD 103 HgR. J Infect Dis 182:1199–1206

    Article  CAS  PubMed  Google Scholar 

  97. John TJ (1993) Immunisation against polioviruses in developing countries. Rev Med Virol 3:149–160

    Article  Google Scholar 

  98. Suharyono O, Simanjuntak C, Witham N, Punjabi N, Heppner DG, Losonsky G, Totosudirjo H, Rifai AR, Clemens J, Lim YL et al (1992) Safety and immunogenicity of single dose live oral cholera vaccine CVD 103-HgR in 5–9- year-old Indonesian children. Lancet 340:689–694

    Article  CAS  PubMed  Google Scholar 

  99. Hallander HO, Paniagua M, Espinoza F, Askelöf P, Corrales E, Ringman M, Storsaeter J (2002) Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children. Vaccine 21:138–145

    Article  CAS  PubMed  Google Scholar 

  100. World Health Organization (2006) Future needs and directions for Shigella vaccines. Wkly Epidemiol Rec 81:51–58

    Google Scholar 

  101. Walker RI (2005) New vaccines against enteric bacteria for children in less developed countries. Expert Rev Vaccines 4:807–812

    Article  CAS  PubMed  Google Scholar 

  102. Barnoy S, Jeong KI, Helm RF, Suvarnapunya AE, Ranallo RT, Tzipori S, Venkatesan MM (2010) Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine 28:1642–54

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Pasteur, Unitié Pathogénie Microbienne Moléculaire - INSERM U786/Réseau International des Instituts Pasteur, 28 rue du Dr Roux, Cedex 15, 75724, Paris, France

    Yves Germani

  2. Institut Pasteur, Unitié Pathogénie Microbienne Moléculaire - INSERM U786, 28 rue du Dr Roux, Cedex 15, 75724, Paris, France

    Philippe J. Sansonetti

Authors
  1. Yves Germani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philippe J. Sansonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yves Germani .

Editor information

Editors and Affiliations

  1. Novartis Vaccines & Diagnostics, Sydney St. 45, Cambridge, 02139, Massachusetts, USA

    Philip R. Dormitzer

  2. Novartis Vaccines & Diagnostics, Inc., Massachusetts Ave. 350, Cambridge, 02139, Massachusetts, USA

    Christian W. Mandl

  3. Novartis Vaccines & Diagnostics S.r.l., Via Fiorentina 1, Siena, 53100, Italy

    Rino Rappuoli

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Basel

About this chapter

Cite this chapter

Germani, Y., Sansonetti, P.J. (2011). Live-Attenuated Shigella Vaccines. Is Encouraging Good Enough?. In: Dormitzer, P., Mandl, C., Rappuoli, R. (eds) Replicating Vaccines. Birkhäuser Advances in Infectious Diseases. Springer, Basel. https://doi.org/10.1007/978-3-0346-0277-8_5

Download citation

Publish with us

Policies and ethics

Search

Navigation